Impact of cushing

Baltagi Myriam; Nacef Ibtissem Ben; Sawsen Essayeh; Sabrine Mekni; Rihab Laamouri; Khiari Karima; Rojbi Imen

doi:10.1530/endoabs.110.EP127

EP127

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 110 EP127 | DOI: 10.1530/endoabs.110.EP127

ECEESPE2025 ePoster Presentations Adrenal and Cardiovascular Endocrinology (170 abstracts)

Impact of cushing’s syndrome treatment on glycemic control and diabetic complications

Baltagi Myriam ¹ , Ibtissem Ben Nacef ¹ , Sawsen Essayeh ¹ , Sabrine Mekni ¹ , Rihab Laamouri ¹ , Khiari Karima ¹ & Rojbi Imen ¹

Author affiliations

¹Hospital of Charles Nicolle, Tunis, Tunisia

JOINT2276

Introduction: Cushing’s syndrome (CS) is associated with a high risk of developing diabetes and related complications. This study assesses the impact of CS treatment on glycemic control and the development of diabetic complications.

Methods: A cohort of 22 CS patients was followed from diagnosis through treatment. Glycemic control (fasting blood glucose, HbA1c) was measured before and after treatment, and diabetic complications (retinopathy, neuropathy, nephropathy) were assessed.

Results: Post-treatment, significant improvements in fasting blood glucose (mean decrease of 23%) and HbA1c (mean decrease of 0.9%) were observed. Diabetic complications were present in 36% of patients at diagnosis but reduced to 15% post-treatment. These improvements were associated with a significant reduction in cortisol levels.

Discussion: The findings suggest that successful treatment of CS not only improves glycemic control but also reduces the risk of developing diabetic complications. The relationship between cortisol levels and glycemic control underscores the role of cortisol in the pathogenesis of diabetes in CS patients.

Conclusion: Treatment of Cushing’s syndrome significantly improves both glycemic control and diabetic complications. Early and effective management of cortisol excess is essential to prevent or mitigate these complications.